Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

China · Delayed Price · Currency is CNY

11.30

-0.36 (-3.09%)

Sep 10, 2026, 1:45 PM CST

Market Cap	4.87B -10.4%
Revenue (ttm)	466.05M +6.2%
Net Income	46.50M +11.8%
EPS	0.12 +33.6%
Shares Out	417.60M
PE Ratio	98.32
Forward PE	n/a
Dividend	0.06 (0.51%)
Ex-Dividend Date	Jun 12, 2026

Volume	6,547,251
Open	11.66
Previous Close	11.66
Day's Range	11.19 - 11.66
52-Week Range	9.01 - 16.95
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:301211

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw material... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1995

Employees 952

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301211

Full Company Profile

Financial Performance

In 2025, SHE:301211's revenue was 453.31 million, an increase of 1.67% compared to the previous year's 445.86 million. Earnings were 34.91 million, a decrease of -61.87%.

Financial Statements